ArticleProceedings of the National Academy of Sciences of the United States of America1999
A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity toward malignant cells.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 59 citations in OpenAlex.
- Biological Activities of Secretory RNases: Focus on Their Oligomerization to Design Antitumor Drugs.Frontiers in immunology · 2019Review
- Surveillance of Tumour Development: The Relationship Between Tumour-Associated RNAs and Ribonucleases.Frontiers in pharmacology · 2019Review
- Small Molecule-Induced Domain Swapping as a Mechanism for Controlling Protein Function and Assembly.Scientific reports · 2017Article
- A nuclear-directed human pancreatic ribonuclease (PE5) targets the metabolic phenotype of cancer cells.Oncotarget · 2016Article
- A Ribonuclease Isolated from Wild Ganoderma Lucidum Suppressed Autophagy and Triggered Apoptosis in Colorectal Cancer Cells.Frontiers in pharmacology · 2016Article
- The nuclear transport capacity of a human-pancreatic ribonuclease variant is critical for its cytotoxicity.Investigational new drugs · 2011Article
- Structural features for the mechanism of antitumor action of a dimeric human pancreatic ribonuclease variant.Protein science : a publication of the Protein Society · 2009Article
- Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity.Current pharmaceutical biotechnology · 2008Review
- Structures of proteins of biomedical interest from the Center for Eukaryotic Structural Genomics.Journal of structural and functional genomics · 2007Review
- Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin.British journal of cancer · 2004Article
- Essential stations in the intracellular pathway of cytotoxic bovine seminal ribonuclease.The Biochemical journal · 2002Article
- Second generation antitumour human RNase: significance of its structural and functional features for the mechanism of antitumour action.The Biochemical journal · 2001Article
- Cancer chemotherapy--ribonucleases to the rescue.Chemistry & biology · 2001Review
- Dimer formation by a "monomeric" protein.Protein science : a publication of the Protein Society · 2000Article
- 1H and 15N sequential assignment and solution secondary structure of 15N labelled human pancreatic ribonuclease.Journal of biomolecular NMR · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monomeric human pancreatic RNase, devoid of any biological activity other than its RNA degrading ability, was engineered into a dimeric protein with a cytotoxic action on mouse and human tumor cells, but lacking any appreciable toxicity on mouse and human normal cells. This dimeric variant of human pancreas RNase selectively sensitizes to apoptotic death cells derived from a human thyroid tumor. Because of its selectivity for tumor cells, and because of its human origin, this protein represents a potentially very attractive, novel tool for anticancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.